GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide growth-hormone-releasing peptide that agonizes the ghrelin/GHS-R1a receptor to stimulate pulsatile GH release; research protocols typically use about 100 mcg subcutaneously, two to three times daily, dosed on an empty stomach.
It has been studied as a growth hormone secretagogue for stimulating endogenous GH and IGF-1 release, and is noted in research for pronounced appetite stimulation via its ghrelin-receptor activity, with additional preclinical interest in recovery and cytoprotective contexts.
GHRP-6 is a synthetic first-generation growth hormone-releasing peptide (GHRP) and hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Research characterizes it as an agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same G-protein-coupled receptor bound by the endogenous hormone ghrelin — expressed in the hypothalamus and anterior-pituitary somatotrophs, where activation triggers phospholipase-C signaling, intracellular calcium release, and pulsatile growth hormone (GH) secretion. It acts on a pathway complementary to growth hormone-releasing hormone (GHRH): GHRP-6 both directly stimulates somatotrophs and amplifies GHRH-driven release while blunting somatostatin's inhibitory tone, so combining a GHRP with a GHRH analog produces a synergistic GH pulse in research.
g. ipamorelin), GHRP-6 is less selective and human studies report accompanying dose-dependent rises in cortisol, ACTH and prolactin, and its ghrelin-receptor agonism produces marked, characteristic appetite stimulation. GHRP-6 is not FDA-approved; it was investigated but never marketed as a drug and is handled as a research compound only.
In research settings it is reconstituted and given subcutaneously, most often at roughly 100 mcg per dose (the reported near-maximal 'saturation dose' of about 1 mcg/kg) two to three times daily on an empty stomach, since food — particularly carbohydrate and fat — blunts the GH response. It is typically explored in cycles rather than continuously because the GHS-R1a receptor desensitizes with sustained use.
Human research reports a rapid GH pulse after subcutaneous administration, with plasma GH typically peaking within roughly 15-60 minutes and returning toward baseline over about 2-3 hours; the appetite-stimulating effect is likewise acute, while any GH-dependent changes in markers such as IGF-1 are studied over weeks.
In research and secretagogue protocols it is most commonly paired with a GHRH analog such as CJC-1295 (no DAC), sermorelin, or tesamorelin to study the synergistic GH pulse produced by engaging the GHRH and ghrelin-receptor pathways together.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.